Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ohio State University Comprehensive Cancer Center
PRIMARY OBJECTIVES:
I. To identify SNPs associated with delayed MTX clearance. II. To explore any association between SNPs and increased toxicity.
OUTLINE: This is an observational study.
Participants undergo blood sample collection and have their medical records reviewed on study.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
\* Adult (age ≥ 18 years at diagnosis)
* Diagnosis of DLBCL or PCNSL
* Planned to undergo treatment with HDMTX (≥ 3 g/m\^2) at the James Cancer Hospital.
Note: patients with CKD are eligible to participate regardless of eGFR provided the treating physician is planning a dose of HDMTX of at least 3 g/ m\^2.
Ability to provide informed consent.
You may not be if
\* Patients with a "currently active" second malignancy that, in the opinion of the principal investigator, will interfere with patient participation, or confound data interpretation
* Pregnancy (positive serum or urine pregnancy test), lactating or breast feeding
* Prisoners or incarcerated patients
* Total bilirubin \> 5 mg/dL
Clareo Health | Pharmacogenomics Effects on High-Dose Methotrexate Clearance in Patients With Diffuse Large B-Cell Lymphoma
